Premium
Thioridazine: resurrection as an antimicrobial agent?
Author(s) -
Thanacoody H. K. R.
Publication year - 2007
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.2007.03021.x
Subject(s) - phenothiazine , thioridazine , antimicrobial , antipsychotic , cardiotoxicity , medicine , pharmacology , drug , biology , microbiology and biotechnology , chemotherapy , chlorpromazine , psychiatry , schizophrenia (object oriented programming)
The emergence of multiresistant bacterial strains and the continuing burden of infectious disease globally point to the urgent need for novel affordable antimicrobial drugs. Thioridazine is a phenothiazine antipsychotic drug with well‐recognized antimicrobial activity, but this property has not been harnessed for clinical use as a result of its central nervous system and cardiac side‐effects. The cardiotoxicity of thioridazine has recently been shown to be structurally specific at a molecular level, whereas its antimicrobial properties are shared by a number of phenothiazine analogues. This raises the possibility that its enantiomers or its inactive metabolite, the ring sulphoxide, may act as a lead compound in the future development of antimicrobial drugs to face the new challenges in infectious disease.